24567-06-4

Usage

Uses

Used in Pharmaceutical Synthesis:
2-BROMO-1-(4-BROMO-PHENYL)-2-PHENYL-ETHANONE is used as a building block for the synthesis of various pharmaceuticals. Its unique structure and reactivity make it a valuable component in the development of new drugs and medicinal compounds.
Used in Organic Compound Synthesis:
2-BROMO-1-(4-BROMO-PHENYL)-2-PHENYL-ETHANONE is utilized as a key intermediate in the synthesis of a wide range of organic compounds. Its bromo-phenyl and phenyl-ethanone functional groups contribute to its high reactivity, facilitating various organic synthesis processes.
Used in Organic Dyes and Pigments Synthesis:
2-BROMO-1-(4-BROMO-PHENYL)-2-PHENYL-ETHANONE is employed as an intermediate in the production of organic dyes and pigments. Its chemical properties allow for the creation of a diverse array of colorants used in various industries.
Used in Research and Development:
Due to its reactivity and unique structure, 2-BROMO-1-(4-BROMO-PHENYL)-2-PHENYL-ETHANONE is often used in research settings to explore new chemical reactions and synthesis pathways. It serves as a valuable tool for scientists and researchers in the field of organic chemistry.
Used in Chemical Industry:
In the chemical industry, 2-BROMO-1-(4-BROMO-PHENYL)-2-PHENYL-ETHANONE is used as a key component in the production of various specialty chemicals and materials. Its versatility and reactivity make it an essential part of the chemical manufacturing process.
Safety Precautions:
Given its reactivity, 2-BROMO-1-(4-BROMO-PHENYL)-2-PHENYL-ETHANONE should be handled with care and stored in a well-ventilated area, away from heat and humidity to ensure safety and stability.

InChI:InChI=1/C14H10Br2O/c15-12-8-6-11(7-9-12)14(17)13(16)10-4-2-1-3-5-10/h1-9,13H

Upstream product

• 2001-29-8 1-(4-bromophenyl)-2-phenyl-ethan-1-one 
• 108-86-1 bromobenzene 
• 103-80-0 phenylacetyl chloride 

Downstream Products

• 88675-41-6 1-(4-bromophenyl)-2-morpholino-2-phenylethanone 
• 492470-94-7 1-(4-bromo-phenyl)-2-(2-methoxy-phenylsulfanyl)-2-phenyl-ethanone 
• 848590-32-9 4-(4-bromophenyl)-5-phenylthiazol-2-amine 
• 405201-34-5 3-(4-bromo-phenyl)-6-hydroxy-2-phenyl-9-oxa-1-thia-cyclopenta[a]naphthalen-8-one 
• 721399-92-4 4-(4-bromo-phenyl)-5-phenyl-thiazole-2-carboxylic acid ethyl ester 
• 1027074-52-7 2-(4-bromophenyl)-3-phenylimidazo[1,2-a]pyridine 
• 1266612-94-5 2-phenyl-3-(p-bromophenyl)imidazo[1,2-a]pyridine 
• 1338597-08-2 [4-(4-bromophenyl)-5-phenylthiazol-2-yl](1-phenyl-1H-[1,2,3]triazol-4-yl)methylamine 
• 3493-17-2 1-(4-bromophenyl)-2-diazo-2-phenylethan-1-one 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of novel pyrrolidone-based derivatives as potent p53-MDM2 inhibitors

Inhibition of the interactions of the tumor suppressor protein p53 with its negative regulators MDM2 in vitro and in vivo, representing a valuable therapeutic strategy for cancer treatment. The natural product chalcone exhibited moderate inhibitory activity against MDM2, thus based on the binding mode between chalcone and MDM2, a hit unsaturated pyrrolidone scaffold was obtained through virtual screening. Several unsaturated pyrrolidone derivatives were synthesized and biological evaluated. As a result, because the three critical hydrophobic pockets of MDM2 were occupied by the substituted-phenyl linked at the pyrrolidone fragment, compound 4 h demonstrated good binding affinity with the MDM2. Additionally, compound 4 h also showed excellent antitumor activity and selectivity, and no cytotoxicity against normal cells in vitro. The further antitumor mechanism studies were indicated that compound 4 h could successfully induce the activation of p53 and corresponding downstream p21 proteins, thus successfully causing HCT116 cell cycle arrest in the G1/M phase and apoptosis. Thus, the novel unsaturated pyrrolidone p53-MDM2 inhibitors could be developed as novel antitumor agents.

Structure-based design and synthesis of antiparasitic pyrrolopyrimidines targeting pteridine reductase 1

The treatment of Human African trypanosomiasis remains a major unmet health need in sub-Saharan Africa. Approaches involving new molecular targets are important; pteridine reductase 1 (PTR1), an enzyme that reduces dihydrobiopterin in Trypanosoma spp., has been identified as a candidate target, and it has been shown previously that substituted pyrrolo[2,3-d]pyrimidines are inhibitors of PTR1 from Trypanosoma brucei (J. Med. Chem. 2010, 53, 221-229). In this study, 61 new pyrrolo[2,3-d]pyrimidines have been prepared, designed with input from new crystal structures of 23 of these compounds complexed with PTR1, and evaluated in screens for enzyme inhibitory activity against PTR1 and in vitro antitrypanosomal activity. Eight compounds were sufficiently active in both screens to take forward to in vivo evaluation. Thus, although evidence for trypanocidal activity in a stage I disease model in mice was obtained, the compounds were too toxic to mice for further development.

Synthesis and antimicrobial activity of a new class of methyleneamine- linked bis-heterocycles

A new class of methyleneamine-linked bis-heterocycles that exhibit antimicrobial activity was synthesized. Bromination of 1 followed by condensation with thiourea gave 3. The reaction of 3 with propargyl bromide in dry toluene under inert atmosphere led to the formation of 4. Its subsequent reaction with different aromatic azides 5 using CuSO4.5H 2O-sodiumascorbate system in a 2:1 mixture of water and tert-butylalcohol yielded the title compounds 6a-j in good yields. The identities of these compounds were confirmed following elemental analysis, IR, 1H, 13C NMR, and mass spectral studies. All the title compounds exhibited pronounced in vitro antibacterial and antifungal activities.

Non-peptidic small molecule inhibitors of XIAP

Non-peptidic small molecule SMAC mimetics were designed and synthesized that bind to the BIR3 domain of XIAP using structure-based design. Substituted five-membered heterocycles such as thiazoles and imidazoles were identified that serve as replacements for peptide fragments of the lead.

COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families, particularly the activity of PPAR.